Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-04-09

Clinical Trial Update: A Study of Olaparib and Durvalumab in Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating olaparib plus durvalumab in prostate cancer was terminated; results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Durvalumab (durvalumab)
  • Olaparib (Olaparib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-04-09